SecBot SecBot
6-K ·Filed Oct 26, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 6/10
Processed57m ago SEC0001648257-26-000068
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000068
Document: hcm-ex99d2.htm0001648257-26-000068
Document: hcm-20261026x6k.htm0001648257-26-000068
Document: 0001648257-26-000068-index-headers.html0001648257-26-000068
Document: 0001648257-26-000068-index.html0001648257-26-000068
Document: 0001648257-26-000068.txt0001648257-26-000068
27 reports for HCM
Performance horizon
92% Hit rate @ T+20 12 of 13 directional calls Went positive at some point 15 of 17 best @ T+60▲ +38.35%Jun 25, 2026
Filters
Rows
Reports for HCM — sortable, filterable
TypeNow
Oct 26, 2026
today
6-K
BULLISH ★ 6/10
—awaiting T+20——
Oct 26, 2026
today
Press Release
BULLISH ★ 7/10
—awaiting T+20——
Oct 26, 2026
today
Press Release
BULLISH ★ 7/10
—awaiting T+20——
Oct 21, 2026
5d ago
6-K
BULLISH ★ 7/10
$14.37awaiting T+20—$14.36 (−0.07%)
Sep 29, 2026
27d ago
6-K
BULLISH ★ 7/10
$14.15awaiting T+20—$14.36 (+1.48%)
Sep 28, 2026
27d ago
6-K
BULLISH ★ 6/10
$14.15awaiting T+20—$14.36 (+1.48%)
Sep 29, 2026
27d ago
Press Release
BULLISH ★ 7/10
$14.63awaiting T+20—$14.36 (−1.85%)
Sep 24, 2026
4w ago
6-K
BULLISH ★ 6/10
$13.90 $14.28▲ +2.73%▲ +3.15%$14.36 (+3.31%)
Sep 24, 2026
4w ago
Press Release
BULLISH ★ 7/10
$13.94 $14.36▲ +3.01%▲ +4.49%$14.36 (+3.01%)
Sep 3, 2026
7w ago
6-K
BULLISH ★ 7/10
$14.11 $14.20▲ +0.64%▲ +1.83%$14.36 (+1.77%)
Showing 10 of 27

US Market Status

Market Closed — Opens in 2h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh HCM Intelligence

Analysis is for subscribers only.

HUTCHMED reported positive results from two Phase III trials (SAFFRON and SANOVO) of ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in EGFR-mutated NSCLC, presented at ESMO 2026 and published in NEJM. SAFFRON showed a 45% PFS risk reduction and 32% OS risk reduction in MET-driven post-TAGRISSO…

Subscribe for Full Access